Anesthetic management for implantation of the Jarvik 2000TM left ventricular assist system

被引:14
作者
Nussmeier, NA
Probert, CB
Hirsch, D
Cooper, JR
Gregoric, ID
Myers, TJ
Frazier, OH
机构
[1] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiovasc Anesthesiol, Houston, TX 77030 USA
[2] St Lukes Episcopal Hosp, Texas Heart Inst, Cullen Cardiovasc Surg Res Labs, Houston, TX 77030 USA
关键词
D O I
10.1213/01.ANE.0000081723.31144.D7
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
The Jarvik 2000 Heart(TM) is a left ventricular assist device that produces continuous nonpulsatile axial flow by means of a single, rotating, vaned impeller. Anesthetic and perioperative considerations of the Jarvik 2000 Heart(TM) differ from those of conventional assist devices. The Jarvik 2000 is implanted within the left ventricle through a left thoracotomy, which is aided by left lung isolation. A brief period of cardiopulmonary bypass and induced ventricular fibrillation facilitate implantation. Transesophageal echocardiography is essential to assure proper intraventricular positioning of the device and aortic outflow, confirmed by observation of aortic valve opening in the presence of adequate left ventricular volume. Because continuous flow devices function best in the presence of lower systemic and pulmonary vascular resistance, milrinone was preferentially used as an inotropic drug. In the first group of 10 patients to receive the Jarvik 2000, the pump provided a cardiac output of up to 8 L/min, depending on preload, afterload, and pump speed. There were no early perioperative deaths. The average support duration was 81.2 days; the range was 13-214 days. Seven of the 10 patients survived to transplantation. Survivors underwent complete physical rehabilitation during pump support.
引用
收藏
页码:964 / 971
页数:8
相关论文
共 18 条
[1]
PATENT FORAMEN OVALE - A CAUSE OF HYPOXEMIA IN PATIENTS ON LEFT-VENTRICULAR SUPPORT [J].
BALDWIN, RT ;
DUNCAN, JM ;
FRAZIER, OH ;
WILANSKY, S .
ANNALS OF THORACIC SURGERY, 1991, 52 (04) :865-867
[2]
Frazier O H., 2001, J Heart Lung Transplant, V20, P201
[3]
Research and development of an implantable, axial-flow left ventricular assist device: The Jarvik 2000 heart [J].
Frazier, OH ;
Myers, TJ ;
Jarvik, RK ;
Westaby, S ;
Pigott, DW ;
Gregoric, ID ;
Khan, T ;
Tamez, DW ;
Conger, JL ;
Macris, MP .
ANNALS OF THORACIC SURGERY, 2001, 71 (03) :S125-S132
[4]
Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system [J].
Frazier, OH ;
Myers, TJ ;
Gregoric, ID ;
Khan, T ;
Delgado, R ;
Croitoru, M ;
Miller, K ;
Jarvik, R ;
Westaby, S .
CIRCULATION, 2002, 105 (24) :2855-2860
[5]
Improved left ventricular function after chronic left ventricular unloading [J].
Frazier, OH ;
Benedict, CR ;
Radovancevic, B ;
Bick, RJ ;
Capek, P ;
Springer, WE ;
Macris, MP ;
Delgado, R ;
Buja, LM .
ANNALS OF THORACIC SURGERY, 1996, 62 (03) :675-681
[6]
Vasopressin in the treatment of Milrinone-induced hypotension in severe heart failure [J].
Gold, J ;
Cullinane, S ;
Chen, J ;
Seo, S ;
Oz, MC ;
Oliver, JA ;
Landry, DW .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (04) :506-508
[7]
REVERSAL OF CHRONIC VENTRICULAR DILATION IN PATIENTS WITH END-STAGE CARDIOMYOPATHY BY PROLONGED MECHANICAL UNLOADING [J].
LEVIN, HR ;
OZ, MC ;
CHEN, JM ;
PACKER, M ;
ROSE, EA ;
BURKHOFF, D .
CIRCULATION, 1995, 91 (11) :2717-2720
[8]
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF APROTININ FOR REDUCING BLOOD-LOSS AND THE REQUIREMENT FOR DONOR-BLOOD TRANSFUSION IN PATIENTS UNDERGOING REPEAT CORONARY-ARTERY BYPASS-GRAFTING [J].
LEVY, JH ;
PIFARRE, R ;
SCHAFF, HV ;
HORROW, JC ;
ALBUS, R ;
SPIESS, B ;
ROSENGART, TK ;
MURRAY, J ;
CLARK, RE ;
SMITH, P ;
NADEL, A ;
BONNEY, SL ;
KLEINFIELD, R .
CIRCULATION, 1995, 92 (08) :2236-2244
[9]
Macris M P, 1994, ASAIO J, V40, pM719, DOI 10.1097/00002480-199407000-00092
[10]
Mets B, 2000, J CARDIOTHOR VASC AN, V14, P316